The Enteroviruses Testing Kit Market is expected to expand at a CAGR of 9.5%, with an estimated market size of USD 1.69 Bn in 2026 and reaching USD 3.20 Bn by 2033. The primary drivers for market growth include the high prevalence of enterovirus infections, increasing demand for efficient diagnosis techniques, rising investments in disease surveillance programs, advancements in molecular diagnostic tools, and growth in healthcare infrastructure.
RT-Polymerase Chain Reaction (RT-PCR is expected to capture the maximum market share of the enteroviruses testing kits in 2026, constituting around 70% of the total market share. The predominance of this technology is due to its high sensitivity, accuracy, and quick detection of enterovirus RNA, making it more reliable as compared to other diagnostic techniques. RT-PCR provides results within hours, whereas conventional viral culture methods may require several days.
In June 2025, AstronDX Technologies (ADT Molecular) announced that its LyteStar Enterovirus HFMD RT-PCR Kit was awarded a tender by the Malaysian National Public Health Laboratories for deployment across the country's national surveillance network.

To learn more about this report, Request Free Sample
Hospitals are anticipated to hold the highest market share of around 58% by 2026 owing to their well-established facilities, higher volume of patients, and presence of sophisticated laboratory facilities. Hospitals remain the primary centers for diagnosing and managing severe enterovirus-associated diseases such as meningitis, encephalitis, infections in newborns, and HFMD.
Moreover, the increase in investment for molecular diagnosis platforms, laboratory automation systems, and public health preparedness programs is enabling hospitals to conduct more tests efficiently without compromising their accuracy and speed.
The Coxsackievirus segment is expected to dominate with a market share of around 33% by 2026 because of the high occurrence of enteroviral illnesses like hand, foot, and mouth disease (HFMD), herpangina, and viral myocarditis. Coxsackieviruses account for a substantial proportion of global enteroviral infections, especially in young children.
In May 2024, iGenesis Bio expanded commercialization of its Coxsackievirus A6/A10/A16/Enterovirus 71 RNA Diagnostic Kit (PCR-Fluorescence), a multiplex qPCR assay capable of simultaneously detecting four major HFMD-related enteroviruses.
The increasing occurrence of enteroviral infections across the globe has led to an increased requirement for enterovirus testing kits. Various diseases are caused by enteroviruses, including HFMD, meningitis, encephalitis, and acute flaccid paralysis. Due to the growing awareness of disease surveillance, healthcare providers have been motivated to use sophisticated molecular tests like RT-PCR. Early diagnosis enables timely clinical intervention and helps reduce disease transmission.
According to the CDC in the U.S., about 10 to 15 million cases of infection by the non-polio enteroviruses occur every year in the country, which clearly highlights the magnitude of infections caused by the enteroviruses.
Improvements in molecular diagnosis are revolutionizing the enteroviruses testing kits market through enhanced accuracy, speed, and efficiency. The real-time reverse transcriptase polymerase chain reaction technology has become the gold standard in enterovirus detection as it is capable of identifying the presence of the virus within minutes, aiding surveillance programs. Multiplex molecular tests have also made it easier for laboratories to detect multiple viruses using one sample from the patient.
Based on the CDC, RT-PCR has been identified as the main diagnostic test for enterovirus diagnosis and typing owing to the rising role of molecular diagnostic tests in managing and monitoring infectious diseases.
|
Current Event |
Description and its Impact |
|
Expansion of Global Enterovirus Surveillance Programs (2025–2026) |
|
|
Rising Hand, Foot and Mouth Disease (HFMD) Outbreak Monitoring Across Asia-Pacific |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report

To learn more about this report, Request Free Sample
North America is estimated to hold around 38% of the global market for Enteroviruses Testing Kits in 2026, owing to superior healthcare infrastructure, adoption of RT-PCR methods, efficient systems for surveillance of infectious diseases, and presence of key players in the field of diagnostics.
Technology will play an increasingly critical role in boosting the market in the region. Diagnostic firms are continuously adding new molecular diagnostic tests using multiplex PCR technology for detecting different types of enteroviruses.
In April 2025, bioMérieux announced the launch of WATCHFIRE, a multiplex PCR-based wastewater surveillance solution for use on the BIOFIRE platform in the United States
The Asia-Pacific region will be the fastest-growing market for the forecast period 2026–2033, growing at a rate of 10.5% per year, owing to the rising prevalence of HFMD, development in healthcare infrastructure, rise in adoption of molecular diagnostics, and increased investment from governments in infectious diseases.
Asian-Pacific governments are enhancing their lab networks and increasing molecular test capacity. For instance, in June 2025, AstronDX Technologies announced that its LyteStar™Enterovirus HFMD RT-PCR Kit was selected by the Malaysian National Public Health Laboratories for nationwide surveillance testing, supporting the detection of Coxsackievirus A6, Coxsackievirus A16, and Enterovirus A71. Such initiatives are expected to accelerate adoption of enterovirus testing kits across the region.
The United States Enteroviruses Testing Kits market is steadily growing due to an increase in disease surveillance programs, the use of molecular testing technologies, and high prevalence of enterovirus infections in the country.
In the competitive U.S. diagnostics market, leading companies are increasingly investing in advanced PCR-based testing and surveillance technologies to improve outbreak detection and laboratory efficiency. For instance, In August 2025, Roche Diagnostics announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its cobas Respiratory 4-flex assay.
The Japan Enteroviruses Testing Kit Market is predicted to grow at a steady pace during the forecast period owing to its well-developed infectious disease surveillance systems in the country and the ongoing developments within molecular diagnostics. Infections caused by enteroviruses such as HFMD cases occur periodically in Japan.
Innovation in molecular diagnostic solutions remains a key growth driver. In May 2025, Sysmex Corporation announced the launch of the CN-6500/CN-3500 automated testing systems in Japan, expanding the company's advanced clinical laboratory testing portfolio.
Some of the major key players in Enteroviruses Testing Kit are Sartorius AG, Abbexa Ltd, Cepheid Inc., Aviva Systems Biology Corporation, Cusabio Technology LLC, ELITech Group SAS, Creative Diagnostics, Quidel Corporation, DiaSorin, bioMérieux, Primerdesign Ltd, and QIAGEN.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.69 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.5% | 2033 Value Projection: | USD 3.20 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Sartorius AG, Abbexa Ltd, Cepheid Inc., Aviva Systems Biology Corporation, Cusabio Technology LLC, ELITech Group SAS, Creative Diagnostics, Quidel Corporation, DiaSorin, bioMérieux, Primerdesign Ltd, and QIAGEN. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients